Agenus enters into contract with Merck for advancement of therapeutic antibodies Agenus Inc.

We are delighted to become working with Merck, who is a head in the developing immuno-oncology space, said Bob Stein, MD, PhD, Chief Scientific Officer of Agenus Inc. We believe our Retrocyte Display technology offers significant advantages for creation of top quality antibody development applicants. This collaboration with Agenus complements our energetic immuno-oncology discovery programs, stated Dr. Eric Rubin, vice president clinical oncology, Merck Analysis Laboratories. We look forward to attempting to advance these programs with the potential to handle the unmet medical desires of people with cancers.At least two studies10,11 focusing on aggressive lowering of lipid levels with high dosages of statins to attain a target LDL cholesterol rate of less than 70 mg per deciliter in very-high-risk patients have shown major reductions in medical end points. A post hoc evaluation of the Treating to New Targets trial 11 showed that, among patients who had accomplished LDL cholesterol values of significantly less than 70 mg per deciliter, the 5-year price of cardiovascular occasions was 25 percent lower among those in the highest quintile of HDL cholesterol levels than among those in the cheapest quintile.